NUFORMIX PLC Logo

NUFORMIX PLC

NFX | IL

Overview

Corporate Details

ISIN(s):
GB00BYW79Y38
LEI:
2138003XG3H3I2J3BJ24
Country:
United Kingdom
Address:
6TH FLOOR, EC3V 0HR LONDON
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Nuformix PLC is a pharmaceutical development company focused on addressing unmet medical needs in fibrosis and oncology. The company's core strategy involves drug repurposing, utilizing its proprietary cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's lead development programs target conditions within oncology supportive care and fibrosis, aiming to create novel treatments from existing medicines.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for NUFORMIX PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-11 08:00
Legal Proceedings Report
US FDA ODD Application Submitted for NXP002
English 13.5 KB
2025-05-29 08:00
Regulatory News Service
Confirmation of European ODD for NXP002
English 13.6 KB
2025-05-28 11:28
Prospectus
Nuformix plc - Single prospectus
English 866.5 KB
2025-05-23 14:19
Prospectus
Prospectus
English 866.5 KB
2025-05-23 14:08
Report Publication Announcement
Publication of a Prospectus
English 13.3 KB
2025-02-28 13:30
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 9.3 KB
2025-02-14 15:18
Report Publication Announcement
Posting of Annual Report and Notice of AGM
English 8.4 KB
2025-01-30 08:00
Share Issue/Capital Change
£168,750 Placing
English 13.1 KB
2025-01-29 08:00
Annual / Quarterly Financial Statement
Annual Results for period ended 30 September 2024
English 414.7 KB
2025-01-28 08:00
Regulatory News Service
NXP002 ODD Application Submitted
English 11.4 KB
2025-01-13 08:00
Regulatory News Service
NXP002 Orphan Drug Designation Draft Application
English 9.6 KB
2024-11-29 18:00
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 9.1 KB
2024-11-05 15:25
Director's Dealing
Director/PDMR Dealings
English 39.9 KB
2024-11-04 11:17
Declaration of Voting Results & Voting Rights Announcements
Result of General Meeting
English 21.2 KB
2024-10-18 11:34
Prospectus
Nuformix plc - Single prospectus
English 1.6 MB

Automate Your Workflow. Get a real-time feed of all NUFORMIX PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for NUFORMIX PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A biopharma firm that developed cannabinoid pain therapies, now in administration and ceased trading.
United Kingdom OCTHF
Oxurion NV Logo
Biopharmaceutical company providing Contract Research Organization (CRO) services to life sciences.
Belgium OXUR
PCI Biotech Holding Logo
Develops light-activated drug delivery for cancer, dermatology, and gene therapy manufacturing.
Norway PCIB
Pentixapharm Holding AG Logo
Develops first-in-class radiopharmaceuticals for cancer diagnosis and therapy (theranostics).
Germany PTP
PharmaLundensis AB Logo
Develops drugs to bind and excrete heavy metals for treating COPD, bronchitis, and depression.
Sweden PHAL
Pharnext Logo France ALPHA
Pherecydes Pharma Logo
Developing precision phage therapies for antibiotic-resistant bacterial infections.
France ALPHE
Philogen Logo
Develops antibody-based biopharmaceuticals for targeted cancer and inflammation treatment.
Italy PHIL
PHYSIOMICS PLC Logo
De-risks oncology drug development for pharma/biotech using modeling and simulation.
United Kingdom PYC
PILA PHARMA AB Logo
Clinical-stage biopharma developing a first-in-class oral drug for diabetes and obesity.
Sweden PILA